Literature DB >> 8123476

Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice.

S L Gibson1, T H Foster, R H Feins, R F Raubertas, M A Fallon, R Hilf.   

Abstract

We have examined the effectiveness of photodynamic therapy against R3230AC rat mammary adenocarcinoma and human mesothelioma as xenografts in the same host. The results demonstrate that the xenografted human tumour is significantly more responsive to photodynamic treatment than the rodent mammary tumour. Studies also showed that the mesothelioma xenograft was fluence rate- and fluence-dependent while the rat tumour exposed to the same conditions demonstrated neither of these dependencies. This disparity in response was not attributable to a difference in either whole-tumour uptake or subcellular distribution of the porphyrin photosensitiser. Analysis of the effects of visible irradiation on cytochrome c oxidase activity, measured in mitochondria prepared from tumours borne on hosts injected with photosensitiser, demonstrated that photoradiation-induced enzyme inhibition was significantly greater in mesothelioma than in R3230AC mammary tumour preparations. However, in parallel studies conducted in vitro, when photosensitiser and light were delivered to previously unperturbed mitochondria, rates of enzyme inhibition were not significantly different. Both tumours were established in long-term cell culture. While the uptake of porphyrin photosensitiser was equivalent in both cell lines, the R3230AC cells displayed a significantly greater photosensitivity than the mesothelioma cells. The data presented here demonstrate that the mechanisms that govern response to photodynamic therapy are complex, but in the case of these two xenografted tumours host response to therapy is not likely to play a significant role.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8123476      PMCID: PMC1968871          DOI: 10.1038/bjc.1994.86

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

Review 2.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Sensitivity of different human lung cancer histologies to photodynamic therapy.

Authors:  R R Perry; W Matthews; J B Mitchell; A Russo; S Evans; H I Pass
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

4.  Direct detection of singlet oxygen sensitized by haematoporphyrin and related compounds.

Authors:  J P Keene; D Kessel; E J Land; R W Redmond; T G Truscott
Journal:  Photochem Photobiol       Date:  1986-02       Impact factor: 3.421

5.  Early biochemical responses to photodynamic therapy monitored by NMR spectroscopy.

Authors:  R Hilf; S L Gibson; D P Penney; T L Ceckler; R G Bryant
Journal:  Photochem Photobiol       Date:  1987-11       Impact factor: 3.421

6.  Evidence against the production of superoxide by photoirradiation of hematoporphyrin derivative.

Authors:  S L Gibson; H J Cohen; R Hilf
Journal:  Photochem Photobiol       Date:  1984-10       Impact factor: 3.421

7.  Effects of insulin in vivo and in vitro on amino acid transport into cells from the R3230AC mammary adenocarcinoma and their relationship to tumor growth.

Authors:  P J Hissin; R Hilf
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

8.  Photodynamic therapy for human malignant mesothelioma in the nude mouse.

Authors:  R H Feins; R Hilf; H Ross; S L Gibson
Journal:  J Surg Res       Date:  1990-10       Impact factor: 2.192

9.  Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma.

Authors:  H B Ris; H J Altermatt; B Nachbur; J C Stewart; Q Wang; C K Lim; R Bonnett; U Althaus
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

10.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy.

Authors:  B W Henderson; S M Waldow; T S Mang; W R Potter; P B Malone; T J Dougherty
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

View more
  6 in total

1.  Differences between cytotoxicity in photodynamic therapy using a pulsed laser and a continuous wave laser: study of oxygen consumption and photobleaching.

Authors:  S Kawauchi; Y Morimoto; S Sato; T Arai; K Seguchi; H Asanuma; M Kikuchi
Journal:  Lasers Med Sci       Date:  2004-01-31       Impact factor: 3.161

2.  A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization?

Authors:  S L Gibson; D J Cupriks; J J Havens; M L Nguyen; R Hilf
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

3.  Transient absorption changes in vivo during photodynamic therapy with pulsed-laser light.

Authors:  B W Pogue; T Momma; H C Wu; T Hasan
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

4.  Response of Photofrin-sensitised mesothelioma xenografts to photodynamic therapy with 514 nm light.

Authors:  T H Foster; S L Gibson; R F Raubertas
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

5.  Uptake and localisation of mTHPC (Foscan) and its 14C-labelled form in normal and tumour tissues of the hamster squamous cell carcinoma model: a comparative study.

Authors:  S Andrejevic Blant; T M Glanzmann; J-P Ballini; G Wagnières; H van den Bergh; P Monnier
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

6.  Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic Therapy.

Authors:  Yi Hong Ong; Joann Miller; Min Yuan; Malavika Chandra; Mirna El Khatib; Sergei A Vinogradov; Mary E Putt; Timothy C Zhu; Keith A Cengel; Arjun G Yodh; Theresa M Busch
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.